GSK and Amicus Therapeutics announce revised Fabry agreement

GlaxoSmithKline (GSK) and Amicus Therapeutics (Nasdaq: FOLD) today announced that Amicus has obtained global rights to develop and commercialise the investigational pharmacological chaperone migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals